Compare PNNT & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNNT | CYRX |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.7M | 421.6M |
| IPO Year | 2007 | 2008 |
| Metric | PNNT | CYRX |
|---|---|---|
| Price | $5.12 | $8.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $5.85 | ★ $12.94 |
| AVG Volume (30 Days) | ★ 839.7K | 321.3K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | ★ 18.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $228,385,000.00 |
| Revenue This Year | N/A | $9.71 |
| Revenue Next Year | N/A | $9.56 |
| P/E Ratio | $13.14 | ★ $5.07 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.84 | $4.63 |
| 52 Week High | $7.53 | $11.45 |
| Indicator | PNNT | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 47.83 |
| Support Level | $4.84 | $8.16 |
| Resistance Level | $6.18 | $9.31 |
| Average True Range (ATR) | 0.15 | 0.50 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 48.04 | 64.00 |
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.